Table 3.
Prognosis of seven operated patients.
| N | Gender | Age | Stage | TMN staging | Stage after surgery | TMN Staging after surgery | Gene | First-line treatment | metastasis | Living | PFS | PFS status | OS | OS status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 50 | IIIA | T1bN2M0 | IIB | T1aN2M0 | EGFR | Icotinib | Unknown | Dead | 8.67 | 0 | / | 1 |
| 2 | Female | 63 | IIIB | T4N2M0 | IIIB | T4N2M0 | EGFR | Gefitinib | Abdominal | Dead | 29.20 | 1 | 34.37 | 1 |
| 3 | Male | 46 | IIIB | T3N2M0 | IIIA | T1cN2M0 | EGFR | Gefitinib + AP | Brain | Living | 13.73 | 1 | 22.57 | 0 |
| 4 | Male | 36 | IIIB | T1cN3M0 | / | / | EGFR | Gefitinib | Progress | Living | 7.50 | 1 | 16.67 | 0 |
| 5 | Male | 56 | IIIB | T4N2M0 | IIIA | T1bN2M0 | EGFR&HER2 | Gefitinib + AP | Bone | Living | 6.60 | 1 | 17.60 | 0 |
| 6 | Female | 63 | IIIA | T1N2M0 | / | / | EGFR | Gefitinib | No metastasis | Living | / | 0 | 44.23 | 0 |
| 7 | Female | 54 | IIIA | T2N2M0 | / | / | EGFR | Gefitinib | Recurrence | Living | 12.23 | 1 | 12.77 | 0 |
AP, Pemetrexed + cisplatin; PFS, progression-free survival, definite from the start of first-line therapy to disease progression; OS, overall survival, definite from pathological diagnosis to patient death.